New drug combo aims to shrink tumors before breast cancer surgery
NCT ID NCT07162051
Summary
This study is testing whether adding a drug called fluzoparib to standard chemotherapy is safe and effective at shrinking tumors before surgery. It is for people with a specific type of early-stage breast cancer (HR+/HER2- and HRD-positive). The goal is to see if this combination leads to less cancer remaining after treatment, which may improve long-term outcomes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+/HER2- EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xijing hospital
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.